Table 1.
Demographic and clinical characteristics.
| Characteristics | Value (n = 19) |
|---|---|
| Age in years, median (IQR) | 69 (64–80) |
| Male, n (%) | 13 (68.4) |
| Context of acquisition, n (%) | |
| Hospital acquired | 11 (57.9) |
| Healthcare-related | 8 (42.1) |
| Underlying diseases, n (%) | 19 (100) |
| Charlson comorbidity index, median (range) | 6 (2–8) |
| Chronic lung disease | 6 (31.6) |
| Solid malignancy | 5 (26.3) |
| Diabetes mellitus | 5 (26.3) |
| Chronic kidney disease | 4 (21.1) |
| Immunosuppression | 3 (15.8) |
| Trauma | 3 (15.8) |
| Hemodyalisis | 1 (5.3) |
| Prior surgery within 30 days, n (%) | 3 (15.8) |
| Prior invasive procedures within 30 days, n (%) | 5 (26.3) |
| Prior ICU stays within 90 days, n (%) | 5 (26.3) |
| Prior bacterial infections, n (%) | 16 (84.2) |
| Prior PA infections within 3 months | 5 (26.3) |
| Prior MDR/XDR pathogens, n (%) | 11 (57.9) |
| Prior antimicrobial use, within 90 days n (%) | 15 (78.9) |
| Carbapenem | 8 (42.1) |
| Glycopeptide | 8 (42.1) |
| Piperacillin/tazobactam | 7 (36.8) |
| Cephalosporin | 5 (26.3) |
| Colistin | 3 (15.8) |
| Fluoroquinolone | 3 (15.8) |
| Aminoglycoside | 2 (10.5) |
| Ceftazidime/avibactam | 1 (5.3) |
| Ceftolozane/tazobactam | 1 (5.3) |
| Other | 8 (42.1) |
| Sequential or combination use, n (%) | 12 (63.2) |
| Length of prior antimicrobial use ≥7 days | 14 (73.7) |
| Indwelling device at infection onset, n (%) | 17 (89.5) |
| Urinary catheter | 14 (73.7) |
| Tracheostomy | 7 (36.8) |
| Central venous catheter | 5 (26.3) |
| Polymicrobial infection, n (%) | 6 (31.6) |
| Infection types, n (%) | |
| UTI | 6 (31.6) |
| BSI | 5 (26.3) |
| ABSSSI | 3 (15.8) |
| HAP | 2 (10.5) |
| VAP | 2 (10.5) |
| PJI | 1 (5.3) |
Pseudomonas aeruginosa, PA; Multidrug-resistant, MDR; ICU, intensive care unit; urinary tract infection, UTI; bloodstream infections, BSI; Hospital-Acquired Pneumonia, HAP; Ventilator-Associated Pneumonia, VAP; acute bacterial skin and skin structure infections, ABSSIs; prosthetic joint infection, PJI.